257 related articles for article (PubMed ID: 12070671)
1. Expression of survivin, an inhibitor of apoptosis protein, in tumors of the nervous system.
Sasaki T; Lopes MB; Hankins GR; Helm GA
Acta Neuropathol; 2002 Jul; 104(1):105-9. PubMed ID: 12070671
[TBL] [Abstract][Full Text] [Related]
2. Microvessel density in brain tumors.
Assimakopoulou M; Sotiropoulou-Bonikou G; Maraziotis T; Papadakis N; Varakis I
Anticancer Res; 1997; 17(6D):4747-53. PubMed ID: 9494601
[TBL] [Abstract][Full Text] [Related]
3. p53 protein alterations in adult astrocytic tumors and oligodendrogliomas.
Nayak A; Ralte AM; Sharma MC; Singh VP; Mahapatra AK; Mehta VS; Sarkar C
Neurol India; 2004 Jun; 52(2):228-32. PubMed ID: 15269478
[TBL] [Abstract][Full Text] [Related]
4. Expression of survivin in astrocytic tumors: correlation with malignant grade and prognosis.
Kajiwara Y; Yamasaki F; Hama S; Yahara K; Yoshioka H; Sugiyama K; Arita K; Kurisu K
Cancer; 2003 Feb; 97(4):1077-83. PubMed ID: 12569609
[TBL] [Abstract][Full Text] [Related]
5. Apolipoprotein D expression in primary brain tumors: analysis by quantitative RT-PCR in formalin-fixed, paraffin-embedded tissue.
Hunter SB; Varma V; Shehata B; Nolen JD; Cohen C; Olson JJ; Ou CY
J Histochem Cytochem; 2005 Aug; 53(8):963-9. PubMed ID: 16055749
[TBL] [Abstract][Full Text] [Related]
6. Expression of survivin and its spliced variants in bladder tumors as a potential prognostic marker.
Nouraee N; Mowla SJ; Ozhand A; Parvin M; Ziaee SA; Hatefi N
Urol J; 2009; 6(2):101-8. PubMed ID: 19472128
[TBL] [Abstract][Full Text] [Related]
7. Nogo-a expression in glial CNS tumors: a tool to differentiate between oligodendrogliomas and other gliomas?
Kuhlmann T; Gutenberg A; Schulten HJ; Paulus W; Rohde V; Bruck W
Am J Surg Pathol; 2008 Oct; 32(10):1444-53. PubMed ID: 18685489
[TBL] [Abstract][Full Text] [Related]
8. Ras p21 expression in brain tumors: elevated expression in malignant astrocytomas and glioblastomas multiforme.
Arvanitis D; Malliri A; Antoniou D; Linardopoulos S; Field JK; Spandidos DA
In Vivo; 1991; 5(4):317-21. PubMed ID: 1667267
[TBL] [Abstract][Full Text] [Related]
9. Immunocytochemical detection of 14-3-3 in primary nervous system tumors.
Cao WD; Zhang X; Zhang JN; Yang ZJ; Zhen HN; Cheng G; Li B; Gao D
J Neurooncol; 2006 Apr; 77(2):125-30. PubMed ID: 16292484
[TBL] [Abstract][Full Text] [Related]
10. [Glial fibrillary acidic protein and central nervous tumors. Immunohistochemical study of a series of 207 cases. 1: Astrocytomas. Glioblastomas. Ependymomas. Papillomas of the choroid plexus].
Pasquier B; Lachard A; Pasquier D; Couderc P; Delpech B; Courel MN
Ann Pathol; 1983; 3(2):127-35. PubMed ID: 6307324
[TBL] [Abstract][Full Text] [Related]
11. Survivin expression in childhood medulloblastomas: a possible diagnostic and prognostic marker.
Bodey B; Bodey V; Siegel SE; Kaiser HE
In Vivo; 2004; 18(6):713-8. PubMed ID: 15646811
[TBL] [Abstract][Full Text] [Related]
12. Expression of survivin in primary glioblastomas.
Das A; Tan WL; Teo J; Smith DR
J Cancer Res Clin Oncol; 2002 Jun; 128(6):302-6. PubMed ID: 12073047
[TBL] [Abstract][Full Text] [Related]
13. Autoantibodies to the inhibitor of apoptosis protein survivin in patients with brain tumors.
Söling A; Plugge EM; Schmitz M; Weigle B; Jacob R; Illert J; Holzhausen HJ; Rainov NG
Int J Oncol; 2007 Jan; 30(1):123-8. PubMed ID: 17143520
[TBL] [Abstract][Full Text] [Related]
14. Mutation-specific IDH1 antibody differentiates oligodendrogliomas and oligoastrocytomas from other brain tumors with oligodendroglioma-like morphology.
Capper D; Reuss D; Schittenhelm J; Hartmann C; Bremer J; Sahm F; Harter PN; Jeibmann A; von Deimling A
Acta Neuropathol; 2011 Feb; 121(2):241-52. PubMed ID: 21069360
[TBL] [Abstract][Full Text] [Related]
15. Q-modification of tRNAs in human brain tumors.
Aytaç U; Gündüz U
Cancer Biochem Biophys; 1994 Sep; 14(2):93-8. PubMed ID: 7889496
[TBL] [Abstract][Full Text] [Related]
16. Caveolin-1 expression is variably displayed in astroglial-derived tumors and absent in oligodendrogliomas: concrete premises for a new reliable diagnostic marker in gliomas.
Cassoni P; Senetta R; Castellano I; Ortolan E; Bosco M; Magnani I; Ducati A
Am J Surg Pathol; 2007 May; 31(5):760-9. PubMed ID: 17460461
[TBL] [Abstract][Full Text] [Related]
17. Expression of tenascin-C in various human brain tumors and its relevance for survival in patients with astrocytoma.
Leins A; Riva P; Lindstedt R; Davidoff MS; Mehraein P; Weis S
Cancer; 2003 Dec; 98(11):2430-9. PubMed ID: 14635078
[TBL] [Abstract][Full Text] [Related]
18. alpha(v)beta(3) Integrin in central nervous system tumors.
Lim M; Guccione S; Haddix T; Sims L; Cheshier S; Chu P; Vogel H; Harsh G
Hum Pathol; 2005 Jun; 36(6):665-9. PubMed ID: 16021573
[TBL] [Abstract][Full Text] [Related]
19. Pitfalls in the assessment of MGMT expression and in its correlation with survival in diffuse astrocytomas: proposal of a feasible immunohistochemical approach.
Capper D; Mittelbronn M; Meyermann R; Schittenhelm J
Acta Neuropathol; 2008 Feb; 115(2):249-59. PubMed ID: 17965865
[TBL] [Abstract][Full Text] [Related]
20. Analysis of the IDH1 codon 132 mutation in brain tumors.
Balss J; Meyer J; Mueller W; Korshunov A; Hartmann C; von Deimling A
Acta Neuropathol; 2008 Dec; 116(6):597-602. PubMed ID: 18985363
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
